Chimerix Stock Discussion

novice g : Going the opposite way despite the good news

101674396 OP novice g : Yes. Hopefully bounce back !!!

Dan’l : ** Shares of biotech Chimerix CMRX
rise 171.68% to $2.35 after the bell
** Company plans to submit an application seeking FDA's accelerated approval in the U.S. for its drug dordaviprone as a treatment for a type of glioma before year-end
** Adds it will be ready for a U.S. launch as early as Q3 2025
** CMRX is seeking approval of dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse
glioma, a type of tumor that forms in the brain
** Up to last close, stock down ~10% YTD
(Reporting bv Sriparna Rov